Literature DB >> 17482796

Role of phosphodiesterase type 3A and 3B in regulating platelet and cardiac function using subtype-selective knockout mice.

Bing Sun1, Haiquan Li, Yasmin Shakur, James Hensley, Steve Hockman, Junichi Kambayashi, Vincent C Manganiello, Yongge Liu.   

Abstract

Phosphodiesterase type 3 (PDE3) is an important regulator of cAMP-mediated responses within the cardiovascular system. PDE3 exists as two subtypes: PDE3A and PDE3B, with distinct cellular and subcellular locations. Due to the lack of subtype-specific pharmacological tools, the definitive role of each subtype in regulating cardiovascular function has not been determined. In this study, we investigated platelet and cardiac function, using PDE3A and PDE3B gene knockout (KO) mice. Platelet-rich-plasma was prepared from the blood of KO and age-matched wild-type (WT) mice. PGE1 (1 microg/mL) almost completely inhibited aggregation of platelets from WT, PDE3A KO and PDE3B KO mice. In platelets from WT mice, cilostamide (100 microM), a selective PDE3 inhibitor, blocked collagen- and ADP-induced aggregation. In contrast, cilostamide had no effect on aggregation of platelets from PDE3A KO mice. In PDE3B KO mice, inhibition of collagen- and ADP-induced platelet aggregation was similar to that in WT mice. The resting intra-platelet cAMP concentration in platelets from PDE3A KO mice was twice that in the WT platelets. After PGE1 (0.1 microg/mL) stimulation, intra-cellular cAMP concentration was increased significantly more in platelets from PDE3A KO mice compared to WT mice. In vivo, PDE3A KO mice were protected against collagen/epinephrine-induced pulmonary thrombosis and death, while no such protection was observed in PDE3B KO mice. The heart rate of PDE3A KO mice was significantly higher, compared with age-matched WT mice, while that of PDE3B KO mice was similar to WT. There was no difference in cardiac contractility between PDE3A or PDE3B KO mice. Heart rate and contractility were increased in a similar dose-dependent fashion by isoproterenol in both types of KO mice. Cilostamide increased heart rate and contractility in WT and PDE3B KO but not in PDE3A KO mice. Compared to WT and PDE3B KO mice, cyclic AMP-PDE activity in membrane fractions prepared from the hearts of PDE3A KO mice was lower and not inhibited by cilostamide. The data suggest that PDE3A is the main subtype of PDE3 expressed in platelets and cardiac ventricular myocytes, and is responsible for the functional changes caused by PDE3 inhibition.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17482796     DOI: 10.1016/j.cellsig.2007.03.012

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  36 in total

1.  Phosphodiesterase 3A (PDE3A) deletion suppresses proliferation of cultured murine vascular smooth muscle cells (VSMCs) via inhibition of mitogen-activated protein kinase (MAPK) signaling and alterations in critical cell cycle regulatory proteins.

Authors:  Najma Begum; Steven Hockman; Vincent C Manganiello
Journal:  J Biol Chem       Date:  2011-06-01       Impact factor: 5.157

Review 2.  cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action.

Authors:  Sharron H Francis; Jennifer L Busch; Jackie D Corbin; David Sibley
Journal:  Pharmacol Rev       Date:  2010-09       Impact factor: 25.468

3.  Targeted disruption of PDE3B, but not PDE3A, protects murine heart from ischemia/reperfusion injury.

Authors:  Youn Wook Chung; Claudia Lagranha; Yong Chen; Junhui Sun; Guang Tong; Steven C Hockman; Faiyaz Ahmad; Shervin G Esfahani; Dahae H Bae; Nazari Polidovitch; Jian Wu; Dong Keun Rhee; Beom Seob Lee; Marjan Gucek; Mathew P Daniels; Christine A Brantner; Peter H Backx; Elizabeth Murphy; Vincent C Manganiello
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-15       Impact factor: 11.205

Review 4.  Cyclic AMP synthesis and hydrolysis in the normal and failing heart.

Authors:  Aziz Guellich; Hind Mehel; Rodolphe Fischmeister
Journal:  Pflugers Arch       Date:  2014-04-24       Impact factor: 3.657

Review 5.  Role of PDE3A in regulation of cell cycle progression in mouse vascular smooth muscle cells and oocytes: implications in cardiovascular diseases and infertility.

Authors:  Najma Begum; Weixing Shen; Vincent Manganiello
Journal:  Curr Opin Pharmacol       Date:  2011-11-01       Impact factor: 5.547

Review 6.  Anti-platelet therapy: phosphodiesterase inhibitors.

Authors:  Paolo Gresele; Stefania Momi; Emanuela Falcinelli
Journal:  Br J Clin Pharmacol       Date:  2011-10       Impact factor: 4.335

Review 7.  Therapeutic potential of PDE modulation in treating heart disease.

Authors:  Walter Knight; Chen Yan
Journal:  Future Med Chem       Date:  2013-09       Impact factor: 3.808

8.  Ca(2+)/calmodulin-activated phosphodiesterase 1A is highly expressed in rabbit cardiac sinoatrial nodal cells and regulates pacemaker function.

Authors:  Yevgeniya O Lukyanenko; Antoine Younes; Alexey E Lyashkov; Kirill V Tarasov; Daniel R Riordon; Joonho Lee; Syevda G Sirenko; Evgeny Kobrinsky; Bruce Ziman; Yelena S Tarasova; Magdalena Juhaszova; Steven J Sollott; David R Graham; Edward G Lakatta
Journal:  J Mol Cell Cardiol       Date:  2016-06-27       Impact factor: 5.000

Review 9.  Targeting phosphodiesterases in anti-platelet therapy.

Authors:  Matthew T Rondina; Andrew S Weyrich
Journal:  Handb Exp Pharmacol       Date:  2012

Review 10.  Cyclic nucleotide phosphodiesterases: important signaling modulators and therapeutic targets.

Authors:  F Ahmad; T Murata; K Shimizu; E Degerman; D Maurice; V Manganiello
Journal:  Oral Dis       Date:  2014-09-12       Impact factor: 3.511

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.